With a distinguished 60-year history, UNI-PHARMA has consistently and devotedly played a leading role not only in the pharmaceutical industry and healthcare sector but also in society and the modern business landscape, driven by extroversion, solidarity, corporate responsibility, and sustainable development.
Founded in 1963 by the visionary pharmacist and researcher Kleon Tsetis, UNI-PHARMA has remained committed to researching, developing, and manufacturing innovative pharmaceutical products in Greece, following the highest Good Manufacturing Practices (GMP) standards. The company’s extensive portfolio includes groundbreaking pharmaceuticals such as T4, Apotel, Salospir, Trebon, and Trebon Grippe Day & Night, as well as medical devices, dietary supplements, vitamins, probiotics, and products that support joint and bone health, immune system enhancement, and gastrointestinal health.
Strategic Investments and Advanced Facilities
Under the leadership of Julia Tseti, President & CEO of OFET, who is a pharmacist, MSc, and Honorary PhD in Pharmacy from NKUA and the University of Patras, the company has undertaken the largest investment in the sector, leading to the creation of a state-of-the-art, bioclimatic UNI-PHARMA manufacturing plant, which has been fully operational since 2015. Today, UNI-PHARMA’s production facilities incorporate the latest technology, robotic systems, and the highest safety standards, marking one of the most significant investments in the Greek pharmaceutical industry in recent years.
Further solidifying its industry leadership, UNI-PHARMA was recognized as a “Growth Winner”, standing out among 6 top-performing companies in Greece in terms of development and extroversion, from a pool of 8,000 businesses. This significant distinction was awarded on November 1, 2023, by GRANT THORNTON & EUROBANK.
Cutting-Edge Investments in Research & Innovation
Over the last decade, OFET has invested more than €120 million, with over €50 million allocated between 2019-2021 to the complete renovation of UNI-PHARMA’s historic first factory on the Athens-Lamia National Road, the establishment of UniHerbo, a new facility dedicated to harnessing Greece’s rich biodiversity, the acquisition of a new warehouse in Kato Kifisia to accommodate raw materials and finished products, and the launch of new production lines at InterMed.
In 2023 alone, UNI-PHARMA produced 1.6 billion tablets and 22 million injectables, further demonstrating its production capacity and industry leadership.
Academic Collaborations & Research Programs
From 2018 to 2024, OFET has self-funded more than 45 internal research programs in collaboration with Greek academic and research institutions. Additionally, 30 research projects have been funded through grants and scholarships awarded by the KLEON TSETIS Foundation (NPO).
OFET has also participated as an industrial partner in 10 national and international research projects, co-funded through the General Secretariat for Research and Innovation (GSRI). During the first half of 2022 alone, the Tsetis Pharmaceutical Group initiated 28 research projects, 8 of which were co-funded by the GSRI, and 12 directly or indirectly focused on utilizing Greece’s biodiversity. With the start of the 2022-2023 academic year, the Group launched five additional research programs, further expanding its commitment to scientific innovation and collaboration.
Sustainability at the Core of Every Step
For the Tsetis Pharmaceutical Group, integrating sustainability into daily operations is essential—not only for environmental protection but also for fostering an ethical corporate culture that impacts its 700 employees.
The Group’s core strategy in Corporate Responsibility and Sustainable Development is guided by its unwavering commitment to ethical business practices, responsibility, and solidarity. UNI-PHARMA has embraced the Sustainable Development Goals (SDGs) and has embedded sustainable practices into its daily operations, striving to enhance its social impact while reducing its environmental and energy footprint.
A key example of this commitment is the bioclimatic UNI-PHARMA plant, which demonstrates how sustainability and innovation go hand in hand. The facility optimizes energy use, promotes recycling, and ensures that the entire production process aligns with sustainable development principles.
Recognized as a Top Employer & Global Supplier
The UNI-PHARMA & InterMed industries are internationally recognized as official suppliers to the United Nations (UN), UNICEF, and the World Health Organization (WHO). Additionally, UNI-PHARMA and InterMed were certified as “Top Employers” in Greece for two consecutive years (2023, 2024) by the Top Employer Institute, highlighting the company’s commitment to creating a superior workplace environment through its Human Resources policies and best practices.
Both companies are also proud members of the UN Global Compact, actively supporting its 10 Principles, which focus on climate action, anti-corruption, responsible business practices, and sustainable development.
Commitment to Society, the Next Generation & the TELEIA Philosophy
UNI-PHARMA takes great pride in its ongoing efforts to support vulnerable communities, research, science, the younger generation, and environmental protection.
The “TELEIA” philosophy (meaning “perfect” in Greek) represents the corporate values of the Tsetis Pharmaceutical Group:
• Teamwork
• Ethos (Uncompromising Ethics)
• Learning (Lifelong Learning)
• Excellence
• Innovation
• Accountability
These corporate values define UNI-PHARMA’s philosophy, guiding its path forward as a leader in pharmaceutical innovation, sustainability, and corporate responsibility.
CGWORKS PRODUCTION